Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
99.3M
-
Number of holders
-
12
-
Total 13F shares, excl. options
-
140K
-
Shares change
-
+51.9K
-
Total reported value, excl. options
-
$247K
-
Value change
-
+$105K
-
Number of buys
-
7
-
Number of sells
-
-4
-
Price
-
$1.75
Significant Holders of PLUS THERAPEUTICS, INC. - Common Stock, $0.001 par value (PSTV) as of Q4 2023
15 filings reported holding PSTV - PLUS THERAPEUTICS, INC. - Common Stock, $0.001 par value as of Q4 2023.
PLUS THERAPEUTICS, INC. - Common Stock, $0.001 par value (PSTV) has 12 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 140K shares
of 99.3M outstanding shares and own 0.14% of the company stock.
Largest 10 shareholders include RENAISSANCE TECHNOLOGIES LLC (33K shares), VANGUARD GROUP INC (32.5K shares), GEODE CAPITAL MANAGEMENT, LLC (26.5K shares), CITADEL ADVISORS LLC (16.8K shares), Ground Swell Capital, LLC (14.3K shares), UBS Group AG (8.9K shares), BlackRock Inc. (6.96K shares), Tower Research Capital LLC (TRC) (572 shares), OSAIC HOLDINGS, INC. (133 shares), and JPMORGAN CHASE & CO (99 shares).
This table shows the top 12 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.